Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine

  • Single-dose vaccine prevented hospitalization and death across all study participants, 28 days after vaccination
  • Vaccine shown to be effective against severe/critical COVID-19 disease as early as seven days after vaccination, with efficacy continuing to increase eight weeks post-vaccination
  • Vaccine also shown to be consistently effective against symptomatic infection, including in South Africa and Brazil where there was a high prevalence of rapidly emerging SARS-CoV-2 variants

Continue reading

Arizona’s bioscience community reports on ‘a robust industry cluster’

The Flinn Foundation hosted its annual bioscience event April 14 to share the impressive progress of Arizona’s growing sector nearly two decades since the launch of Arizona’s Bioscience Roadmap. 

The virtual event featured a keynote address by Tom Osha of Wexford Science and Technology and a mix of live presentations and videos showcasing the innovative and growing bioscience ecosystem throughout Arizona, including Flagstaff, metro Phoenix, and the Tucson and Yuma regions. Continue reading

Vaccine Navigators Available to Assist Medicaid Members with Appointment and Transportation Scheduling 

The Arizona Health Care Cost Containment System (AHCCCS), in partnership with Crisis Response Network, announces a new COVID-19 appointment and transportation navigation program for Medicaid members. Now, Medicaid members who need assistance scheduling a COVID-19 vaccine appointment, as well as transportation to and from that appointment, can call 1-844-542-8201, 8 a.m. to 5 p.m., seven days a week.Continue reading

OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response

OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
vMYX-hIL-12/Dec produces functional protein (hIL-12) from transgenes in vivo and in a dose and time responsive in vitro and has demonstrated anti-tumor efficacy in a xenograft human lung cancer model

Quantitative systems pharmacology modeling suggests IV administration of multi-armed myxoma virotherapy to fall within known safety margins at the planned doses of oncolytic immunotherapiesContinue reading

Indoor Drive-Thru Vaccination Site Opens at Dexcom in Mesa

“At Dexcom, our mission is to help improve the health of others, so when asked if we could provide our facility for an indoor mass-vaccination site, we didn’t hesitate,” said Jim Kasselmann, senior director of manufacturing in Mesa for Dexcom. “We are proud to manufacture our products in Mesa, and anytime we can help our local community, that is what we will do.”Continue reading